Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213028458> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4213028458 endingPage "1395" @default.
- W4213028458 startingPage "1387" @default.
- W4213028458 abstract "BACKGROUND Elevated levels of soluble intercellular adhesion molecules (sICAM)-1 in serum have been shown to be associated with poor prognosis in Hodgkin disease and non-Hodgkin lymphomas. However, little is known about the significance of serum sICAM-1 levels in extranodal lymphomas. The objective of this study was to examine the sICAM-1 levels in patients with extranodal lymphomas and the correlation with clinical features and outcome. METHODS The serum levels of sICAM-1 were measured in stored serum samples of 88 patients with primary extranodal lymphomas at presentation using enzyme-linked immunoassay. The correlation between serum sICAM-1 levels and clinical characteristics, pathologic features, and disease outcome were retrospectively analyzed. RESULTS Serum sICAM-1 levels in patients with extranodal lymphomas (mean, 372 ± 198.8 ng/mL; interquartile range, 252–466 ng/mL) were significantly higher than that of healthy control subjects (mean, 214 ± 78.5 ng/mL; interquartile range, 160–241 ng/mL; P < 0.0001). High serum sICAM-1 levels (≥ 371 ng/mL) were significantly associated with B-symptoms, elevated lactate dehydrogenase level, advanced stage (III/IV; Ann Arbor Staging System), and poor response to therapy. Univariate analysis demonstrated a significantly poorer 5-year disease free (41% vs. 64%; P = 0.01) and overall (44% vs. 73%; P = 0.003) survival in patients with high serum sICAM-1 as compared with those with normal sICAM-1. In multivariate analysis, both disease free (P = 0.0085) and overall (P = 0.0003) survival were independently associated with high serum sICAM-1 levels. CONCLUSIONS Serum sICAM-1 levels are elevated in patients with extranodal lymphomas. In these individuals, high serum sICAM-1 levels are associated with adverse disease features and poor outcome. Cancer 2000;89:1387–95. © 2000 American Cancer Society." @default.
- W4213028458 created "2022-02-24" @default.
- W4213028458 creator A5024483334 @default.
- W4213028458 creator A5042632184 @default.
- W4213028458 date "2000-09-15" @default.
- W4213028458 modified "2023-09-26" @default.
- W4213028458 title "The prognostic significance of serum levels of soluble intercellular adhesion molecules‐1 in patients with primary extranodal non‐Hodgkin lymphomas" @default.
- W4213028458 doi "https://doi.org/10.1002/1097-0142(20000915)89:6<1387::aid-cncr24>3.3.co;2-v" @default.
- W4213028458 hasPublicationYear "2000" @default.
- W4213028458 type Work @default.
- W4213028458 citedByCount "1" @default.
- W4213028458 crossrefType "journal-article" @default.
- W4213028458 hasAuthorship W4213028458A5024483334 @default.
- W4213028458 hasAuthorship W4213028458A5042632184 @default.
- W4213028458 hasBestOaLocation W42130284581 @default.
- W4213028458 hasConcept C119060515 @default.
- W4213028458 hasConcept C126322002 @default.
- W4213028458 hasConcept C142724271 @default.
- W4213028458 hasConcept C144301174 @default.
- W4213028458 hasConcept C146357865 @default.
- W4213028458 hasConcept C151730666 @default.
- W4213028458 hasConcept C181199279 @default.
- W4213028458 hasConcept C185592680 @default.
- W4213028458 hasConcept C2777318727 @default.
- W4213028458 hasConcept C2779338263 @default.
- W4213028458 hasConcept C38180746 @default.
- W4213028458 hasConcept C55493867 @default.
- W4213028458 hasConcept C63363279 @default.
- W4213028458 hasConcept C71924100 @default.
- W4213028458 hasConcept C86803240 @default.
- W4213028458 hasConcept C90924648 @default.
- W4213028458 hasConceptScore W4213028458C119060515 @default.
- W4213028458 hasConceptScore W4213028458C126322002 @default.
- W4213028458 hasConceptScore W4213028458C142724271 @default.
- W4213028458 hasConceptScore W4213028458C144301174 @default.
- W4213028458 hasConceptScore W4213028458C146357865 @default.
- W4213028458 hasConceptScore W4213028458C151730666 @default.
- W4213028458 hasConceptScore W4213028458C181199279 @default.
- W4213028458 hasConceptScore W4213028458C185592680 @default.
- W4213028458 hasConceptScore W4213028458C2777318727 @default.
- W4213028458 hasConceptScore W4213028458C2779338263 @default.
- W4213028458 hasConceptScore W4213028458C38180746 @default.
- W4213028458 hasConceptScore W4213028458C55493867 @default.
- W4213028458 hasConceptScore W4213028458C63363279 @default.
- W4213028458 hasConceptScore W4213028458C71924100 @default.
- W4213028458 hasConceptScore W4213028458C86803240 @default.
- W4213028458 hasConceptScore W4213028458C90924648 @default.
- W4213028458 hasIssue "6" @default.
- W4213028458 hasLocation W42130284581 @default.
- W4213028458 hasOpenAccess W4213028458 @default.
- W4213028458 hasPrimaryLocation W42130284581 @default.
- W4213028458 hasRelatedWork W196233337 @default.
- W4213028458 hasRelatedWork W1978901582 @default.
- W4213028458 hasRelatedWork W1995338334 @default.
- W4213028458 hasRelatedWork W2367054191 @default.
- W4213028458 hasRelatedWork W2367617697 @default.
- W4213028458 hasRelatedWork W2411442805 @default.
- W4213028458 hasRelatedWork W2415741046 @default.
- W4213028458 hasRelatedWork W2611655540 @default.
- W4213028458 hasRelatedWork W3115337401 @default.
- W4213028458 hasRelatedWork W3140385248 @default.
- W4213028458 hasVolume "89" @default.
- W4213028458 isParatext "false" @default.
- W4213028458 isRetracted "false" @default.
- W4213028458 workType "article" @default.